Bassim MK, Berliner KI, et al: Otol Neurotol 2010; 31 (June): 567-573 The radiation literature shows a large amount of variation in the outcomes type of data for radiation therapy for vestibular schwannomas. Studies with longer follow-up report significantly worse outcomes.
Tinnitus Signals Increased Risk for VS Growth

Predictors of Vestibular Schwannoma Growth and Clinical Implications.
Agrawal Y, Clark JH, et al: Otol Neurotol 2010; 31 (July): 807-812 A third of patients who initially choose observation for managing vestibular schwannomas later change to radiation or surgery. Larger tumors and tinnitus predict an increased risk of failing conservative management.
Background: Vestibular schwannomas (VS) are now often found at a small size with minimal symptoms. Management of these tumors is shifting toward serial observation with MRI. However, tumor growth remains a risk and has historically been difficult to predict. Objective: To describe the initially observed natural history of VS and to identify the factors associated with changes in management strategy. Design: Retrospective review. Participants: 180 patients with unilateral sporadic VS who presented during a 10-year study interval. Methods: To be included in the study, patients needed to have had at least 2 clinic visits during the initial year of presentation. Schwannomas of nerves other than cranial nerve VIII were excluded, as were cases of neurofibromatosis type 2. Patients were also excluded from this study if there was a history of prior radiation or surgery. Results: 37% of patients experienced tumor growth, which was manifested after a mean duration of 32 months. Overall, 35% of patients pursued a change in their treatment strategy to either surgery or radiation. Patients who changed treatment strategies were significantly more likely to have had larger tumors at presentation, to have tumors located in the cerebellopontine angle, and to have tinnitus. The tinnitus association was especially interesting, and the presence of tinnitus at presentation increased the odds of tumor growth 3-fold. In >80% of patients who opted to change treatment strategy, the reason for the change was tumor growth. Twelve patients who had tumor growth opted to continue observation, a decision which was usually due to poor health or advanced age. No significant differences were found between those who changed treatment strategy and those who remained with observation with respect to age, gender, laterality, presence of hearing loss, vertigo at initial presentation, or length of follow-up.
Conclusions:
The results of this study demonstrate that about a third of patients with acoustic neuromas who initially opt for observation will eventually change to treatment with radiation or surgery. The most interesting correlation that this study reports is the strong correlation between tumor growth and tinnitus. The authors suggest that tinnitus may be a marker of more biologically active tumors. Reviewer's Comments: One major bias of this study is that those who were chosen for observation tended to be older and have smaller tumors than those who initially chose surgery or radiation. However, this paper will cause me to more carefully consider tinnitus complaints in a patient presenting with a small VS. (ReviewerBenjamin T. Crane, MD).
Survival Not Changed By Intracranial Extension
Outcomes Following Temporal Bone Resection. In patients with malignant tumors of the temporal bone, the survival rates were similar for those with or without intracranial extension. However, the prognosis was worse in patients with recurrent tumors.
Background:
Patients with lateral skull base malignancy can be treated with a temporal bone resection, but they still tend to have a poor prognosis. Variables such as recurrent disease and intracranial extension are thought by some to be contraindications to surgery. Objective: To report the outcome of temporal bone resection for lateral skull base malignancy in a series of patients. Design: Retrospective review. Participants: 65 patients who underwent temporal bone resection for epithelial and salivary gland tumors were included in this review. More than 75% of these patients were men, and the mean age was 65 years. Methods: Patients underwent treatment between 2002 and 2009. Tumors were staged using American Joint Committee on Cancer guidelines. Most of these patients also underwent neck dissections and postoperative radiation. Rehabilitative procedures were performed when cranial nerves were taken. Facial reanimation procedures were also included in all patients. Free flaps were used in 72% of patients. Results: The median follow-up was 10 months (range, 1 month to 5 years). At the last follow-up, about 50% of patients were disease-free. The 2-year disease-free survival rate was 68%. Recurrence was twice as likely in patients who had recurrent disease at the initial surgery. Nodal metastasis was also associated with a poor prognosis and dropped the 2-year survival rate to 34%. Intracranial extension did not have a significant effect on survival. Conclusions: This study found that those with recurrent disease could still benefit from temporal bone resection, although they had a worse prognosis. Patients with intracranial extension had a rate of survival similar to those who did not have intracranial extension. Reviewer's Comments: I found this paper to be interesting because the results challenged two common assumptions about malignant tumors of the temporal bone: (1) patients with recurrent disease are not curable, and (2) patients with intracranial extension have an extremely poor prognosis. In this series, some patients with recurrent disease were cured, although the prognosis was worse in these cases. Surprisingly, intracranial extension did not affect survival. Perhaps because of the greater use of free tissue transfer flaps, these authors were able to report results better than historical averages. However, this retrospective study had variation in both the extent of disease and tumor histology. No doubt, some patients who had intracranial extension or recurrent disease were not offered temporal bone resection. Therefore, the cohort reported in this study represents a select group of patients. (Reviewer-Benjamin T. Crane, MD).
Gentamicin, Endolymphatic Shunts Still Duking It Out
Outcomes of Endolymphatic Shunt Surgery for Ménière's Disease: Comparison With Intratympanic Gentamicin on Vertigo
Control and Hearing Loss. The authors conclude that the best chance of hearing preservation and vertigo control is with an endolymphatic shunt, but it is unclear if hearing preservation was a goal in the patients treated with gentamicin.
Background: Endolymphatic shunts have long been a staple of therapy for Ménière's disease (MD), although their popularity has decreased somewhat in the past decade with the increasing use of intratympanic injections. According to the results of 2 surveys conducted within the past decade, the use of intratympanic gentamicin was found to surpass the use of endolymphatic shunts. However, the rates of hearing preservation and vertigo control have not been directly compared between these 2 interventions. Objective: To compare hearing and vertigo control outcomes between intratympanic gentamicin and endolymphatic shunts used to treat MD. Design: Retrospective review and meta-analysis. Participants: 183 patients who had an endolymphatic shunt at the authors' institution, and 203 patients from 6 published gentamicin studies. Methods: Shunt patients had a diagnosis of unilateral definite MD and were excluded if they had prior surgical treatment. A total 203 patients from 6 studies of intratympanic gentamicin were chosen for review based on their inclusion of individual data, as well as pre-and post-treatment hearing preservation and post-treatment vertigo control.
Results:
The shunt and gentamicin groups were not similar with respect to preoperative hearing level: good pretreatment hearing (pure tone average >50 dB) was found in 60% of the shunt group and in 36% of the gentamicin group. The percentage of complete vertigo control and hearing preservation was 62% in the shunt group and 56% in the gentamicin group. These groups also differed with respect to vertigo outcome. The gentamicin group had 71% complete vertigo control compared with 86% for shunts. However, the gentamicin outcomes were not consistent between studies: rates of hearing preservation and vertigo control ranged from 40% to 87%.
Conclusions:
The authors believe that endolymphatic shunt surgery was more likely to achieve vertigo control with hearing preservation than was intratympanic gentamicin for the treatment of MD. Reviewer's Comments: This study has some flaws. First, gentamicin patients had significantly worse hearing than shunt patients prior to treatment. Only a third of gentamicin patients had a pure tone average <50 dB. Most of these patients got very high gentamicin doses, further indicating that hearing preservation was probably not a concern. The most common dose of gentamicin averaged >200 mg, and in the next two largest series, it was at least 100 mg. Second, inclusion criteria required gentamicin studies to report individual results, excluding many larger studies. For example, a study of 78 patients published last year from Johns Hopkins reported a 96% rate of vertigo control with gentamicin, which was significantly better than any endolymphatic shunt series. Finally, most published series on gentamicin included 1-year to 2-year follow-ups, but no followup was required or described for the shunt patients. (Reviewer-Benjamin T. Crane, MD). An increase in tympanic membrane stiffness was found ipsilateral to TMJ disease when compared with the contralateral side. Further study is needed because this finding could be due to causes other than middle ear pathology.
TMJ Associated With Increased Middle Ear Stiffness
Background: Temporomandibular joint (TMJ) disorders are a common cause of ear pain. These patients frequently also have tinnitus and hearing loss in the affected ear at a rate higher than would be expected from chance alone. The cause of the association remains unclear, but it has been hypothesized to originate in the central nervous system. Objective: To determine if multiple frequency tympanometry (MFT) can uncover a middle ear abnormality in TMJ disorder. Design: Prospective clinical study. Participants: 40 patients with unilateral TMJ disorder of >1 month's duration. Methods: The diagnosis of TMJ was confirmed using clinical criteria. Additionally, all patients had x-rays to exclude dental pathology. The ear workup included 226 Hz tympanometry, MFT, audiometry, and brainstem evoked potentials. Results were compared between the ear ipsilateral to the TMJ and the contralateral side. Results: Pain around the ear was reported in 72% of the participants, tinnitus by 70%, fullness by 30%, and subjective hearing loss by 30%. Subjective hearing loss was significantly more common in patients older than age 45 years when compared with the younger group. Auditory brainstem responses (ABR) were normal. Standard tympanometry revealed type A tympanometry in all patients. Pure-tone audiometry revealed symmetric responses in all patients. Resonant frequency, as measured with MFT, was higher on the TMJ side in 85% of patients (statistically significant difference). This difference tended to be greater in patients younger than age 45 years. Conclusions: TMJ disorders increase the stiffness of the middle ear as measured using MFT. Reviewer's Comments: The observation that those with TMJ disorder tend to have a higher incidence of ear pathology, such as tinnitus and subjective hearing loss, is an interesting one. However, standard tympanometry, audiometry, and ABR are normal in these patients and, until now, these patients have had only subjective ear symptoms. This paper is the first to report an objective ear finding in these patients, which was a subtle but significant increase in tympanic stiffness as detected by MFT. This finding could be due to the pain causing increased tensor tympani or stapedius tension rather than middle ear pathology. (Reviewer-Benjamin T. Crane, MD).
